Pharmacokinetics of a Cholesterol-conjugated Aptamer Against the Hepatitis C Virus (HCV) NS5B Protein

Molecular Therapy Nucleic Acids

Volumn 4, Issue , 2015, Pages e254-

  Lee, Chang Ho ^a   Lee, Soo Han ^b   Kim, Ji Hyun ^a   Noh, Yook Hwan ^c   Noh, Gyu Jeong ^d   Lee, Seong Wook ^a  

^a Department of Molecular Biology Institute of Nanosensor and Biotechnology Research Institute of Advanced Omics   (South Korea)

^b Konkuk University   (South Korea)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Asan Medical Center   (South Korea)

Author keywords

Aptamer; cholesterol conjugation; HCV; NS5B; pharmacokinetics

Indexed keywords

ANTIVIRUS AGENT; APTAMER; CHOLESTEROL; LIPOPROTEIN; NONSTRUCTURAL PROTEIN 5B;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG TOLERABILITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INNATE IMMUNITY; LIPOPROTEIN BLOOD LEVEL; LIVER CELL; MALE; MOUSE; NONHUMAN; PHARMACOKINETIC PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PLASMA HALF LIFE; PRIORITY JOURNAL; REPLICON CELL; RNA REPLICATION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 84943257110     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2015.30     Document Type: Article

References (43)

1. Alter, MJ (2007). Epidemiology of hepatitis C virus infection. World J Gastroenterol 13: 2436-2441.
2. Levrero, M (2006). Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25: 3834-3847.
3. Fried, MW, Shiffman, ML, Reddy, KR, Smith, C, Marinos, G, Goncąles, FL Jr et al. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
4. Kieffer, TL, Kwong, AD and Picchio, GR (2010). Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 65: 202-212.
5. Kieffer, TL, Sarrazin, C, Miller, JS, Welker, MW, Forestier, N, Reesink, HW et al. (2007). Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46: 631-639.
6. Kaur, G and Roy, I (2008). Therapeutic applications of aptamers. Expert Opin Investig Drugs 17: 43-60.
7. Que-Gewirth, NS and Sullenger, BA (2007). Gene therapy progress and prospects: RNA aptamers. Gene Ther 14: 283-291.
8. Ellington, AD and Szostak, JW (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822.
9. Tuerk, C and Gold, L (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505-510.
10. Hwang, B, Cho, JS, Yeo, HJ, Kim, JH, Chung, KM, Han, K et al. (2004). Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus. RNA 10: 1277-1290.
11. Nishikawa, F, Funaji, K, Fukuda, K and Nishikawa, S (2004). In vitro selection of RNA aptamers against the HCV NS3 helicase domain. Oligonucleotides 14: 114-129.
12. Nishikawa, F, Kakiuchi, N, Funaji, K, Fukuda, K, Sekiya, S and Nishikawa, S (2003). Inhibition of HCV NS3 protease by RNA aptamers in cells. Nucleic Acids Res 31: 1935-1943.
13. Umehara, T, Fukuda, K, Nishikawa, F, Sekiya, S, Kohara, M, Hasegawa, T et al. (2004). Designing and analysis of a potent bi-functional aptamers that inhibit protease and helicase activities of HCV NS3. Nucleic Acids Symp Ser 48: 195-196.
14. Bellecave, P, Andreola, ML, Ventura, M, Tarrago-Litvak, L, Litvak, S and Astier-Gin, T (2003). Selection of DNA aptamers that bind the RNA-dependent RNA polymerase of hepatitis C virus and inhibit viral RNA synthesis in vitro. Oligonucleotides 13: 455-463.
15. Bellecave, P, Cazenave, C, Rumi, J, Staedel, C, Cosnefroy, O, Andreola, ML et al. (2008). Inhibition of hepatitis C virus (HCV) RNA polymerase by DNA aptamers: mechanism of inhibition of in vitro RNA synthesis and effect on HCV-infected cells. Antimicrob Agents Chemother 52: 2097-2110.
16. Biroccio, A, Hamm, J, Incitti, I, De Francesco, R and Tomei, L (2002). Selection of RNA aptamers that are specific and high-affinity ligands of the hepatitis C virus RNA-dependent RNA polymerase. J Virol 76: 3688-3696.
17. Jones, LA, Clancy, LE, Rawlinson, WD and White, PA (2006). High-affinity aptamers to subtype 3a hepatitis C virus polymerase display genotypic specificity. Antimicrob Agents Chemother 50: 3019-3027.
18. Lee, CH, Lee, YJ, Kim, JH, Lim, JH, Kim, JH, Han, W et al. (2013). Inhibition of hepatitis C virus (HCV) replication by specific RNA aptamers against HCV NS5B RNA replicase. J Virol 87: 7064-7074.
19. Yang, D, Meng, X, Yu, Q, Xu, L, Long, Y, Liu, B et al. (2013). Inhibition of hepatitis C virus infection by DNA aptamer against envelope protein. Antimicrob Agents Chemother 57: 4937-4944.
20. Kikuchi, K, Umehara, T, Fukuda, K, Kuno, A, Hasegawa, T and Nishikawa, S (2005). A hepatitis C virus (HCV) internal ribosome entry site (IRES) domain III-IV-targeted aptamer inhibits translation by binding to an apical loop of domain IIId. Nucleic Acids Res 33: 683-692.
21. Marton, S, Romero-López, C and Berzal-Herranz, A (2013). RNA aptamer-mediated interference of HCV replication by targeting the CRE-5BSL3.2 domain. J Viral Hepat 20: 103-112.
22. Levin, AA, Yu, RZ and Geary, RS. Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. In: Crooke ST (ed.). Antisense Drug Technology: Principles, Strategies and Applications. 2nd edn. CRC Press, Boca Raton, 2007.
23. Bouchard, PR, Hutabarat, RM and Thompson, KM (2010). Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol 50: 237-257.
24. Gabrielsson, J and Weiner, D. Pharmacokinetic & Pharmacodynamic Data Analysis. Swedish Pharmaceutical Press, Stockholm, 2007.
25. de Smidt, PC, Le Doan, T, de Falco, S and van Berkel, TJ (1991). Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution. Nucleic Acids Res 19: 4695-4700.
26. Healy, JM, Lewis, SD, Kurz, M, Boomer, RM, Thompson, KM, Wilson, C et al. (2004). Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm Res 21: 2234-2246.
27. Krützfeldt, J, Rajewsky, N, Braich, R, Rajeev, KG, Tuschl, T, Manoharan, M et al. (2005). Silencing of microRNAs in vivo with 'antagomirs'. Nature 438: 685-689.
28. Takei, Y, Kadomatsu, K, Itoh, H, Sato, W, Nakazawa, K, Kubota, S et al. (2002). 5'-,3'-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine. Its design and application for cancer therapy. J Biol Chem 277: 23800-23806.
29. Yoneda, K, Sugimoto, K, Shiraki, K, Tanaka, J, Beppu, T, Fuke, H et al. (2008). Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-kappaB activation and apoptosis. Int J Oncol 33: 929-936.
30. Mercer, DF, Schiller, DE, Elliott, JF, Douglas, DN, Hao, C, Rinfret, A et al. (2001). Hepatitis C virus replication in mice with chimeric human livers. Nat Med 7: 927-933.
31. Hummel, J, McKendrick, S, Brindley, C and French, R (2009). Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat 8: 38-49.
32. Takizawa, Y, Nishimura, H, Morota, T, Tomisawa, H, Takeda, S and Aburada, M (2004). Pharmacokinetics of TJ-8117 (Onpi-to), a drug for renal failure (I): Plasma concentration, distribution and excretion of [3H]-(-)epicatechin 3-O-gallate in rats and dogs. Eur J Drug Metab Pharmacokinet 29: 91-101.
33. Drolet, DW, Nelson, J, Tucker, CE, Zack, PM, Nixon, K, Bolin, R et al. (2000). Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 17: 1503-1510.
34. Lee, YJ, Han, SR, Kim, NY, Lee, SH, Jeong, JS and Lee, SW (2012). An RNA aptamer that binds carcinoembryonic antigen inhibits hepatic metastasis of colon cancer cells in mice. Gastroenterology 143: 155-65.e8.
35. McCauley, TG, Kurz, JC, Merlino, PG, Lewis, SD, Gilbert, M, Epstein, DM et al. (2006). Pharmacologic and pharmacokinetic assessment of anti-TGFbeta2 aptamers in rabbit plasma and aqueous humor. Pharm Res 23: 303-311.
36. Talbot, LJ, Mi, Z, Bhattacharya, SD, Kim, V, Guo, H and Kuo, PC (2011). Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells. Surgery 150: 224-230.
37. Rowland, M and Tozer, TN. Kinetics following an extravascular dose. Clinical Pharmacokinetics and Pharmacodynamics. 4th edn. Lippincott Williams & Wilkins, Baltimore, 2011. pp. 159-182.
38. Krieger, N, Lohmann, V and Bartenschlager, R (2001). Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 75: 4614-4624.
39. Shin, KS, Lim, JH, Kim, JH, Myung, H and Lee, SW (2006). Inhibition of the replication of hepatitis C virus replicon with nuclease-resistant RNA aptamers. J Microbiol Biotechnol 16: 1634-1639.
40. Lohmann, V, Körner, F, Koch, J, Herian, U, Theilmann, L and Bartenschlager, R (1999). Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110-113.
41. Lee, CH, Kim, JH, Kim, HW, Myung, H and Lee, SW (2012). Hepatitis C virus replicationspecific inhibition of microRNA activity with self-cleavable allosteric ribozyme. Nucleic Acid Ther 22: 17-29.
42. Silahtaroglu, AN, Nolting, D, Dyrskjøt, L, Berezikov, E, Møller, M, Tommerup, N et al. (2007). Detection of microRNAs in frozen tissue sections by fluorescence in situ hybridization using locked nucleic acid probes and tyramide signal amplification. Nat Protoc 2: 2520-2528.
43. NRC. Guide for the Care and Use of Laboratory Animals. National Academies Press: Washington, DC, 1996.